Vitamin C supplementation lowers advanced glycation end products (<scp>AGEs</scp>) and malondialdehyde (<scp>MDA</scp>) in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled clinical trial

This study evaluated how daily vitamin C administration impacts systemic oxidative stress and inflammation its safety in T2D patients. randomized, double-blinded, placebo-controlled, parallel-arm clinical trial included 70 patients with T2D. They were allocated to receive either 500 mg/day of or a matching placebo for 8 weeks. Of the subjects assigned trial, 57 statistical analysis (vitamin C: n = 32, placebo: 25). Inflammatory markers, including advanced glycation end products (AGEs), malondialdehyde (MDA), oxidation protein (AOPP), oxidized low-density lipoprotein (ox-LDL), highly sensitive C-reactive (hs-CRP), tumor necrosis factor-α (TNF-α), ferric reducing ability plasma (FRAP) measured at baseline trial. In addition, tolerance was evaluated. A nutritionist visited all participants standard diabetic regimen. Following supplementation, serum levels MDA (p-value < .001) AGEs .002) demonstrated significant decrease after controlling multiple confounders, age, blood pressure, waist circumference, HbA1C, TG, LDL-C, while no changes observed AOPP .234) ox-LDL .480). The FRAP showed an increasing trend as antioxidant marker but not statistically .312). hs-CRP TNF-α had (p-value: .899 .454, respectively). Also, major adverse events observed. Vitamin supplementation may be beneficial